Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 28, 1996, and the nine-month period ended on the same date. Haemonetics Corporation is a medical technology company incorporated in Massachusetts, specializing in blood management systems, including disposable products and equipment for surgical and blood bank applications. As of the reporting date, there were 27,062,670 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Dec 28, 1996 | Nine Months Ended Dec 28, 1996 |
|---|---|---|
| Net Revenues | $76.6 million | $226.5 million |
| Gross Profit | $38.1 million (49.7% margin) | $120.3 million (53.1% margin) |
| Operating Income | $10.3 million (13.5% margin) | $37.4 million (16.5% margin) |
| Net Income | $7.0 million ($0.26/share) | $25.1 million ($0.91/share) |
| Cash from Operations | N/A | $25.7 million |
| Capital Expenditures | N/A | ($26.7 million) |
| Working Capital | $107.1 million (as of Dec 28, 1996) | |
| Total Debt (Current + Long-term) | $25.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10% for the quarter and 9% for the nine-month period compared to the prior year, driven by growth in both domestic and international markets for disposables and equipment.
- Margin Compression: Gross profit margins declined to 49.7% (quarter) and 53.1% (nine months) from 56.0% and 55.4% respectively in the prior year. This was attributed to a shift in product mix toward lower-margin commercial plasma disposables, pricing pressures from managed care, and the strengthening of the U.S. dollar.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased as a percentage of revenue due to start-up costs for a new domestic service business, regulatory costs for red cell apheresis, and the creation of a centralized European distribution center.
- Cash Flow: Operating cash flow for the nine-month period decreased significantly to $25.7 million from $45.5 million in the prior year, primarily due to increased working capital requirements (accounts receivable and sales-type leases) associated with business growth.
Outlook, Risks, and Management Commentary
- Outlook: Management does not anticipate a change in the trends affecting margins (product mix, pricing pressure, currency) in the near term. The effective tax rate is expected to remain at approximately 35% for the full fiscal year 1997.
- Liquidity: The company maintains $107.1 million in working capital. Management believes committed bank lines and internally generated funds are sufficient to meet future liquidity and capital needs.
- Capital Allocation: Significant capital expenditures ($26.7 million for the nine months) were directed toward equipment for the U.S. commercial plasma business, blood bank services, and facility investments.
- Risks: Key risks include continued pricing pressures from managed care, foreign exchange rate fluctuations (hedged via forward contracts totaling $117.1 million), and the costs associated with launching new service businesses.
Investor Verification Checklist
- Verify the sustainability of revenue growth given the reported decline in gross margins.
- Assess the impact of the new domestic service business on future profitability and cash flow.
- Monitor the effectiveness of foreign currency hedging strategies given the company's significant international exposure (approx. 61-63% of revenue).
- Review the trajectory of accounts receivable and sales-type leases to ensure they do not continue to strain operating cash flow.
- Confirm the timeline for the new European distribution center to reach operational efficiency.